<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-167814</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Interferon alpha-2a as alternative treatment for conjunctival squamous cell carcinoma</dc:title>
<dc:description xml:lang="en">Case report: A 35 year-old male patient with a history of HIV infection characterized by progressive tumour growth in bulbar conjunctiva of the left eye, corresponding to conjunctival squamous cell carcinoma that responded to treatment with interferon alpha-2a. Discussion: Interferon alpha-2b has been used at conjunctival level as a topical immunomodulator treatment, with complete remission of epithelial neoplasms being observed. However, there have not been any previous publications on the use of interferon alpha-2a, which differs from interferon alpha-2b in a single amino acid, for the treatment of conjunctival squamous cell carcinoma (AU)</dc:description>
<dc:creator>Cruzado-Sánchez, D</dc:creator>
<dc:creator>Álvarez-Matos, SE</dc:creator>
<dc:creator>Serpa-Frías, S</dc:creator>
<dc:creator>Tellez, WA</dc:creator>
<dc:creator>Salas-Diaz, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Paciente varón de 35 años con antecedente de infección por VIH, caracterizado por tumoración de crecimiento progresivo en conjuntiva bulbar de ojo izquierdo correspondiente a un carcinoma conjuntival de células escamosas que responde a tratamiento con interferón alfa-2a. Discusión: A nivel conjuntival, el interferón alfa-2b tópico ha sido utilizado como tratamiento inmunomodulador, con el que se observó remisión completa de las neoplasias epiteliales; sin embargo, no se ha publicado el uso del interferón alfa-2a para el tratamiento de carcinoma conjuntival de células escamosas, el cual difiere del intererón alfa-2b en un solo aminoácido (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;92(11): 539-542, nov. 2017. ilus</dc:source>
<dc:identifier>ibc-167814</dc:identifier>
<dc:title xml:lang="es">Interferón alfa-2a como tratamiento alternativo para el carcinoma conjuntival de células escamosas</dc:title>
<dc:subject>^d24718^s22012</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d3254</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d2337</dc:subject>
<dc:subject>^d30033^s22073</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:type>article</dc:type>
<dc:date>201711</dc:date>
</metadata>
</record>
</ibecs-document>
